Data supplements
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Engineered Nanobodies Bind Theranostic Main Group Metals
- Phase II Trial Assessing the Repeatability and Tumor Uptake of [68Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma
- Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein {alpha}
- Two birds with one stone: human SIRP{alpha} nanobodies for functional modulation and in vivo imaging of myeloid cells
- Single-Domain Antibody Theranostics on the Horizon
- Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment
- Imaging Reveals Importance of Shape and Flexibility for Glomerular Filtration of Biologics
- Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
- PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody
- Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer
- First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer
- Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology
- 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
- Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
- Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
- Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET
- Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2
- Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
- 99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice
- Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling
- Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies